EP
TAK icon

Elkfork Partners’s Takeda Pharmaceutical TAK Stock Holding History

Elkfork Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,168
Closed -$251K – 1068
2019
Q2 		$251K Buy
+14,168
New +$258K 0.01% 766

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Elkfork Partners's TAK Position: Q3 2019 in Review

Elkfork Partners sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 14,168 shares — an estimated $251K sold.

Elkfork Partners first reported a position in TAK in Q2 2019 and held it in 1 quarter. The position peaked at $251K in Q2 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Elkfork Partners reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Elkfork Partners sold 14,168 Takeda Pharmaceutical shares in Q3 2019, an estimated $251K.
  • Elkfork Partners first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 1 quarter.
  • Elkfork Partners's Takeda Pharmaceutical position peaked at $251K in Q2 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.